Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) price on Friday, January 17, fall -1.71% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.58.
A look at the stock’s price movement, the close in the last trading session was $0.59, moving within a range at $0.5688 and $0.59. The beta value (5-Year monthly) was 2.247. Turning to its 52-week performance, $2.05 and $0.53 were the 52-week high and 52-week low respectively. Overall, ADAP moved -1.94% over the past month.
Adaptimmune Therapeutics Plc ADR’s market cap currently stands at around $148.38 million, with investors looking forward to this quarter’s earnings report slated for in February.
The average forecast suggests up to a 3,697.50% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 183.73M, representing a 204.78% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ADAP is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 4 recommend ADAP as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ADAP’s current price about -3.41% and -11.06% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 41.93, while 7-day volatility ratio is 8.62% and 8.11% in the 30-day chart. Further, Adaptimmune Therapeutics Plc ADR (ADAP) has a beta value of 2.41, and an average true range (ATR) of 0.05. Analysts have given the company’s stock an average 52-week price target of $4, forecast between a low of $4 and high of $4. Looking at the price targets, the low is -589.66% off current price level while to achieve the yearly target high, price needs to move -589.66%. Nonetheless, investors will most likely welcome a -589.66% jump to $4 which is the analysts’ median price.
If we refocus on Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP), historical trading data shows that trading volumes averaged 1.7 over the past 10 days and 2.18 million over the past 3 months. The company’s latest data on shares outstanding shows there are 255.70 million shares.
The 11.49% of Adaptimmune Therapeutics Plc ADR’s shares are in the hands of company insiders while institutional holders own 41.99% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 5.35 million on 2024-10-31, giving us a short ratio of 4.71. The data shows that as of 2024-10-31 short interest in Adaptimmune Therapeutics Plc ADR (ADAP) stood at 314.00003 of shares outstanding, with shares short falling to 6.09 million registered in 2024-09-30. Current price change has pushed the stock 7.65% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ADAP stock continues to rise going into the next quarter.
